Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claim about cyclosporine emulsion acting as a partial immunomodulator in keratoconjunctivitis sicca–related presumed tear suppression is directly supported by the provided FDA label text in Section 12.1.
Category Scores
Accurate Statements
Cyclosporine emulsion acts as a partial immunomodulator in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
Supported by FDA label 12.1: “In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, cyclosporine emulsion is thought to act as a partial immunomodulator. The exact mechanism of action is not known.”
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is limited to a labeled description of mechanism of action and does not introduce dosing, contraindication, warnings, or safety guidance not present in the supplied label excerpt.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement